Departments of Obstetrics and Gynecology, Chinese PLA General Hospital, Beijing 100853, China.
Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang 222001, China.
Chin J Nat Med. 2013 Nov;11(6):666-72. doi: 10.1016/S1875-5364(13)60077-1.
To analyze the composition of the Chinese herbal medicine Sanjie Zhentong Capsule (SJZTC) and test the therapeutic efficacy of each component in a rat model of endometriosis.
A rapid resolution liquid chromatography (RRLC) method coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (Q-TOF MS) has been developed for the analysis of SJZTC. Two main ingredients, Drac(h)onis sanguis and saponin, were tested in the endometriosis model. Sixty Lewis female rats were in the estrous cycle stage when endometriosis was experimentally initiated by peritoneal implantation of endometrial tissue. Four weeks later, a second laparotomy was performed and implant volumes were measured. After that, the implanted rats were randomized into five study groups: control group (treatment with saline), anastrozole group (treatment with anastrole, 18 μg per day), loureirin A group (treated with loureirin A, 97.2 mg), ginsenoside Re group (treated with ginsenoside Re, 64.8 mg), and SJZTC groups (treated with SJZTC, 86.4 mg) administered once a day for 4 weeks via gastric gavage. After four weeks of treatment, a third laparotomy was performed, implant volumes were re-measured, and the levels of vascular endothelial growth factor (VEGF) and tumor necrosis factor-alpha (TNF-α) were tested.
A total of 38 compounds including, both the target and unknown compounds, were rapidly predicted in the capsule extract by the developed method. Compared with the control group, the anastrozole group, loureirin A group, ginsenoside Re group, and SJZTC treated group showed smaller implant volumes, as well as lower levels of VEGF and TNF-α in the peritoneal focus (P < 0.01 for all comparisons). Furthermore, parameters in the groups treated with SJZTC, loureirin A and ginsenoside Re were significantly better than the control group and the anastrozole group. These results indicate that SJZTC and its two main components are effective in reducing the development of endometriosis.
分析中药散结镇痛胶囊（SJZTC）的组成，并测试各成分在子宫内膜异位症大鼠模型中的治疗效果。
建立了一种快速分辨液相色谱（RRLC）与电喷雾电离四极杆飞行时间串联质谱（Q-TOF MS）联用的方法，用于 SJZTC 的分析。在子宫内膜异位症模型中测试了两种主要成分，龙血竭和皂苷。60 只雌性 Lewis 大鼠在动情周期阶段，通过腹膜内植入子宫内膜组织来建立子宫内膜异位症模型。4 周后，进行第二次剖腹手术，测量植入物体积。然后，将植入大鼠随机分为 5 个研究组：对照组（生理盐水处理）、阿那曲唑组（阿那曲唑，每天 18μg）、芫花素 A 组（芫花素 A，97.2mg）、人参皂苷 Re 组（人参皂苷 Re，64.8mg）和 SJZTC 组（SJZTC，86.4mg），每天通过灌胃给药一次，连续 4 周。治疗 4 周后，再次进行第三次剖腹手术，测量植入物体积，并检测血管内皮生长因子（VEGF）和肿瘤坏死因子-α（TNF-α）的水平。
通过建立的方法，在胶囊提取物中快速预测到 38 种化合物，包括目标化合物和未知化合物。与对照组相比，阿那曲唑组、芫花素 A 组、人参皂苷 Re 组和 SJZTC 治疗组的植入物体积较小，腹腔焦点中的 VEGF 和 TNF-α水平也较低（所有比较均 P <0.01）。此外，SJZTC、芫花素 A 和人参皂苷 Re 治疗组的参数明显优于对照组和阿那曲唑组。这些结果表明 SJZTC 及其两种主要成分可有效减少子宫内膜异位症的发展。
